Literature DB >> 31428388

Lymphedema: An early sign of rodent ulcer metastasis leads to timely intervention.

Caroline Mann1, Stephan Rietz1, Ronald Amedee2, Hadrian Schepler1.   

Abstract

Basal cell carcinoma has a potential for early and late metastasis. Depending on the location of the primary site, the relevant lymphatic drainage routes have to be monitored. Regional lymph edema may be a first indicator for metastasizing disease.

Entities:  

Keywords:  basalcell carcinoma metastasis; lymphedema; surgical intervention; ultrasound

Year:  2019        PMID: 31428388      PMCID: PMC6692983          DOI: 10.1002/ccr3.2285

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


INTRODUCTION

Basal cell carcinoma is the most common skin cancer developing with various clinical and histologic features mostly in parts of the body exposed to UV‐light. Especially, the head and neck area is at risk. Some tumors develop in other parts of the body and may be part of a rare genetic syndrome.1 Therapy for locally advanced tumors includes surgical excisions with clear margins, laser or radiotherapy, and in advanced stages hedgehog pathway inhibitors, chemotherapy, and PDL‐1 immunotherapy in study protocols.2 Metastatic disease is unexpected and occurs according to the literature in only 0.025%‐0.55%.3

CASE REPORT

A 50‐year‐old otherwise healthy, nonimmunosuppressed male presented with several basal cell carcinomas and a rodent ulcer, on his right shoulder, which was resected with clear margins followed by radiotherapy to the primary tumor site (Figure 1). Because of the size of the primary tumor, 60 Gy was administered.
Figure 1

Rodent ulcer of the right shoulder before surgical intervention

Rodent ulcer of the right shoulder before surgical intervention Initial ultrasound examination of the right axilla showed a lymph node measuring 1.8 × 1 × 1 cm, which was classified as unspecific lymph node enlargement. The patient presented 3 years after initial treatment with sudden extensive lymph edema of the right upper extremity. On clinical examination, there was no lymph node enlargement palpable in the right axilla; however, ultrasound revealed only one suspicious lymph node (Figure 2).
Figure 2

Hypoechogenic, round‐shaped lymph node in the right axillary region showing a loss of hilum with peripheral perfusion

Hypoechogenic, round‐shaped lymph node in the right axillary region showing a loss of hilum with peripheral perfusion Preoperative PET‐CT demonstrated two lymph nodes in the right axillary region and no evidence of further metastasis (Figure 3). The patient was admitted for lymphadenectomy. Histologic examination revealed only one metastatic lymph node with basaloid differentiation and perinodular infiltration and one lymph node with unspecific inflammation.
Figure 3

PET‐CT scan showing lymphedema of the right arm and localized FDG avidity in the right axilla

PET‐CT scan showing lymphedema of the right arm and localized FDG avidity in the right axilla In addition, final histopathology revealed carcinomatous hemangiosis. Because of previous radiotherapy, only limited additional radiotherapy with 50 Gy was feasible. After 12 months, there is no sign of recurrent disease.

DISCUSSION

This is the first time that lymphedema of the upper extremity was indicative for metastatic disease in basal cell carcinoma. Since his first description in 1894 by Beadles et al, only approximately 400 cases of metastatic disease have been reported in the literature.4, 5 It remains to be debated if the axilla lymph node at the time of primary treatment was involved by micrometastasis and included in the field of radiotherapy with later growth leading to lymphedema.

CONCLUSION

There are still ongoing discussions how to treat metastasized basal cell carcinoma, thus making individual strategies necessary. Individualized therapy depends on tumor load and localization. Today's options include hedgehog inhibitors, surgery, and radiotherapy. Recent studies include PD1 inhibitor therapy and tumor vaccination (Jäger, unpublished data/personal communication). In this case, lymphedema, as an early warning sign, led to timely intervention and further recurrence free survival till date.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

CM: is a patient physician and main clinical researcher. SR: is a consultant reviewing the clinical data. RA: is a senior advisor and academic teacher. HS: is a senior author and primary surgeon.
  3 in total

1.  Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.

Authors:  Stefanie Fischer; Omar Hasan Ali; Wolfram Jochum; Thomas Kluckert; Lukas Flatz; Marco Siano
Journal:  Oncol Res Treat       Date:  2018-05-03       Impact factor: 2.825

Review 2.  Nevoid basal cell carcinoma syndrome (Gorlin syndrome).

Authors:  Lorenzo Lo Muzio
Journal:  Orphanet J Rare Dis       Date:  2008-11-25       Impact factor: 4.123

3.  Metastatic Basal Cell Carcinoma: A Rare Manifestation of a Common Disease.

Authors:  Paola Piva de Freitas; César Galusni Senna; Mayara Tabai; Carlos Takahiro Chone; Albina Altemani
Journal:  Case Rep Med       Date:  2017-11-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.